| Literature DB >> 31921954 |
Ashraf Yusuf Rangrez1, Lucia Kilian1, Katharina Stiebeling1, Sven Dittmann2, Pankaj Yadav3, Eric Schulze-Bahr2, Norbert Frey1, Derk Frank1.
Abstract
We recently reported a novel, heterozygous, and non-synonymous ACTC1 mutation (p.Gly247Asp or G247D) in a large, multi-generational family, causing atrial-septal defect followed by late-onset dilated cardiomyopathy (DCM). We also found that the G247D ACTC1 mutation negatively regulated serum response (SRF)-signaling thereby contributing to the late-onset DCM observed in human patients carrying this mutation ("A cardiac α-actin (ACTC1) p. Gly247Asp mutation inhibits SRF-signaling in vitro in neonatal rat cardiomyocytes" [1]). There are some ACTC1 mutations known to date, majority of which, though, have not been investigated for their functional consequence. We thus aimed at determining the functional impact of various ACTC1 gene mutations on SRF-signaling using SM22-response element driven firefly luciferase activity assays in C2C12 cells.Entities:
Keywords: ACTC1; Atrial septal defect; Gene mutation; Serum response factor
Year: 2020 PMID: 31921954 PMCID: PMC6950782 DOI: 10.1016/j.dib.2019.105071
Source DB: PubMed Journal: Data Brief ISSN: 2352-3409
Fig. 1Known human ACTC1 gene mutations are depicted pictorially. Mutations are described as the nuclic acid change in the coding DNA and the resulting amino acid change in the protein in brackets. ATG = start codon, c = coding DNA, p = protein, TAA = stop codon, UTR = untranslated region.
Location and associated cardiac phenotypes of human ACTC1 gene mutations. Listed are the description of the mutation on DNA and protein level as descripted in this article (and corresponding description according to the reference sequence from the NCBI database), the exon and the protein domain in which the mutation is located and reported cardiac phenotypes. ASD = atrial septal defect, ASD II = ostium secundum atrial septal defect, HCM = hypertrophic cardiomyopathy, LVNCC = left ventricular non compaction cardiomyopathy, MR = mitral regurgitation, RCM = restrictive cardiomyopathy.
| coding DNA: | exon | protein: | protein domain | clinical cardiac phenotype | references |
|---|---|---|---|---|---|
| c.301G>A | 3 | p.E99K | subdomain 1 | ASD, LVNCC, apical HCM, RCM, MR | Olson et al. 2000 [ |
| c.373A>G | 3 | p.M123V | subdomain 1, hydrophobic core | ASD-II | Matsson et al. 2008 [ |
| c.740G>A | 5 | p.G245D | subdomain 3 | ASD-II, atrial arrhythmias, late onset DCM, | Frank et al. 2019 [ |
| c.941G>A | 6 | p.R312H | subdomain 3, tropomyosin binding site | DCM | Olson et al.1998 [ |
| c.1088A>G | 7 | p.E361G | subdomain 3, Actinin binding site | DCM | Olson et al.1998 [ |
Fig. 2Relative luciferase activity in C2C12 cells deduced from SM22 reporter-driven firefly luciferase for the human wild-type and ACTC1-mutant proteins. (n = 6/group).
Specifications Table
| Subject | Cardiology and Cardiovascular Medicine |
| Specific subject area | Molecular cardiology (molecular mechanisms of dilated cardiomyopathy) |
| Type of data | Table |
| How data were acquired | Chemiluminescence was measured photometrically on an Infinite M200 PRO system (Tecan). |
| Data format | Analysed |
| Parameters for data collection | ACTC1 gene mutations mentioned in |
| Description of data collection | C2C12 cells were transfected with either wild-type or one of the mutant ACTC1 together with Renilla-luciferase and Firefly-luciferase. Media was changed post 6 h transfections and cells were further incubated for 48 h. Cells were then washed twice with PBS, lysed with the active lysis buffer and the assay was performed using dual luciferase reporter assay kit (Promega), according to the manufacturer's instructions. Bioluminescence was measured photometrically on an Infinite M200 PRO system (Tecan). All the experiments were performed in hexaplicate and repeated two times. |
| Data source location | Institution: University Medical Centre Kiel |
| Data accessibility | With the article |
| Related research article | Rangrez et al., A cardiac α-actin (ACTC1) p. Gly247Asp mutation inhibits SRF-signaling in vitro in neonatal rat cardiomyocytes. Biochem Biophys Res Commun. |
Present data is a preliminary evidence of the differential functional impact ACTC1 genetic mutations on SRF-signaling These data provide a basis molecular cardiologists working on ACTC1 for further evaluation of these ACTC1 mutations for genotype-phenotype correlations Functional differences obtained here highlight the fact that different localizations of known or yet to be identified ACTC1 mutations affect the tertiary structure thereby affecting protein-protein interactions, which needs to be experimentally validated. |